Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

It is time for chronotherapy!

B Coudert1, G Bjarnason, C Focan

  • 1Centre Georges François Leclerc, 1, rue du Professeur-Marion, BP 77980, 21079 cedex, Dijon, France. bcoudert@dijon.fnclcc.fr

Pathologie-Biologie
|July 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Auto-Immune Pancreatitis with Pseudo-Tumoral Mass Induced by Pembrolizumab in a Woman suffering from Metastatic Urothelial Carcinoma: Case Report and Literature survey.

Acta gastro-enterologica Belgica·2026
Same author

Stauffer syndrome : a rare paraneoplastic complication of renal cell carcinoma to be kept in mind. Case report and literature survey.

Acta gastro-enterologica Belgica·2024
Same author

Patient management after primary rectal cancer diagnosis. Special focus on surgical treatment for non-metastatic disease.

Acta chirurgica Belgica·2023
Same author

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.

ESMO open·2021
Same author

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

ESMO open·2021
Same author

Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.

European journal of clinical pharmacology·2021
Same journal

Pathologie-biologie·2020
Same journal

Antibacterial and antibiofilm activities of Laurus nobilis L. essential oil against Staphylococcus aureus strains associated with oral infections.

Pathologie-biologie·2015
Same journal

[Not Available].

Pathologie-biologie·2015
Same journal

Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol.

Pathologie-biologie·2015
Same journal

Biological diagnosis of diabetes mellitus.

Pathologie-biologie·2015
Same journal

Association of CagPAI integrity with severeness of Helicobacter pylori infection in patients with gastritis.

Pathologie-biologie·2015
See all related articles

The EORTC Chronotherapy Group (CTG) investigates timed cancer treatments based on biological rhythms. This research aims to improve cancer therapy delivery by adapting to circadian patterns.

Area of Science:

  • Oncology
  • Chronobiology
  • Clinical Cancer Research

Background:

  • The EORTC Chronotherapy Group (CTG) evolved from the International Organisation for Cancer Chronotherapy (IOCC) in 1996.
  • The IOCC pioneered large-scale international chronotherapy trials to assess timed cancer treatment delivery based on biological rhythms.
  • Technological advancements included programmable pumps for cytotoxic chronodelivery and actigraphs for monitoring circadian rhythm alterations in cancer patients.

Purpose of the Study:

  • To investigate the relevance of chronomodulated (timed) cancer therapy administration based on biological rhythms.
  • To leverage the EORTC's expertise in clinical cancer research, inter-group collaborations, and translational research for advancing cancer chronotherapy.
  • To expand the network of chronotherapy research, integrating expertise from experimental chronobiology to disease-specific management and patient outcomes.

Related Experiment Videos

Main Methods:

  • Conducting multicentre international chronotherapy trials.
  • Developing and utilizing programmable pumps for timed cytotoxic drug delivery.
  • Employing actigraph devices to monitor circadian rhythm alterations in cancer patients.

Main Results:

  • The EORTC CTG has expanded significantly, now including 48 centers across 12 countries.
  • Currently, seven multicentre chronotherapy trials are underway, evaluating the impact of circadian rhythm-adapted cancer treatment.
  • The group is fostering collaborations to establish a comprehensive chronotherapy network.

Conclusions:

  • Cancer chronotherapy, by adapting treatment delivery to circadian rhythms, holds significant potential for improving cancer care.
  • The EORTC CTG plays a crucial role in advancing this field through collaborative research and development.
  • Further research is needed to fully establish the benefits of chronotherapy across various cancer types and patient populations.